文献速递甲状腺疾病

甲状腺功能减退患者在线调查显示明显治疗不满

An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction.
PubMed 文献 · Thyroid · 2018-04-05

该在线调查通过美国甲状腺协会网站等渠道招募甲状腺功能减退患者,共12,146人完成问卷,评估其对治疗和医生的满意度。在无自报抑郁、应激或合并症的3670人中,使用干燥甲状腺提取物(DTE)者治疗满意度中位数为7,高于左甲状腺素(LT4)组的5和LT4+碘塞罗宁(LT4+LT3)组的6。作者认为部分甲减患者对现有治疗或医生不满意,未来研究应探讨对DTE的偏好是否与三碘甲状腺原氨酸水平或其他原因相关。

要点

  • 共12,146名甲减患者完成在线调查,总体治疗满意度中位数为5(IQR 3-8)。
  • 无自报抑郁、应激或合并症的3670人中,DTE组满意度中位数7高于LT4组的5和LT4+LT3组的6。
  • DTE组报告体重管理、疲劳/精力、情绪和记忆问题的比例低于LT4或LT4+LT3组。

核心结论

  • 部分甲状腺功能减退患者对当前治疗或医生不满意,使用DTE者对治疗和医生的满意度较高。
  • 研究设计无法提供机制解释,未来研究应探讨对DTE的偏好是否与三碘甲状腺原氨酸水平或其他未明确原因相关。

研究设计与样本

  • 在线调查,问卷发布在美国甲状腺协会网站并转发至多个群体,共12,146名甲状腺功能减退患者完成。
  • 受访者按治疗分为LT4、LT4+LT3和DTE三组,并报告性别、年龄、病因、治疗时长、合并诊断和症状。
  • 满意度及对医生知识、新治疗需求、疾病生活影响等采用1-10分评分。

主要发现

  • 总体治疗满意度中位数为5(IQR=3-8)。
  • 在无自报抑郁、应激或合并症的3670人中,DTE组治疗满意度中位数为7(IQR=5-9),LT4组为5(IQR=3-7),LT4+LT3组为6(IQR=3-8)。
  • DTE组报告体重管理、疲劳/精力、情绪和记忆问题的可能性低于LT4或LT4+LT3组。

关键数值与推荐

  • 总体满意度中位数5(IQR=3-8)。
  • 无自报抑郁、应激或合并症者中,DTE组满意度中位数7(IQR=5-9),LT4组5(IQR=3-7),LT4+LT3组6(IQR=3-8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究设计无法提供机制解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 15% more patients taking levothyroxine (LT4) report impaired quality of life compared to controls. This could be explained by additional diagnoses independently affecting quality of life and complicating assignment of causation. This study sought to investigate the underpinnings of reduced quality of life in hypothyroid patients and to provide data for discussion at a symposium addressing hypothyroidism. METHODS: An online survey for hypothyroid patients was posted on the American Thyroid Association Web site and forwarded to multiple groups. Respondents were asked to rank satisfaction with their treatment for hypothyroidism and their treating physician. They also ranked their perception regarding physician knowledge about hypothyroidism treatments, need for new treatments, and life impact of hypothyroidism on a scale of 1-10. Respondents reported the therapy they were taking, categorized as LT4, LT4 and liothyronine (LT4 + LT3), or desiccated thyroid extract (DTE). They also reported sex, age, cause of hypothyroidism, duration of treatment, additional diagnoses, and prevalence of symptoms. RESULTS: A total of 12,146 individuals completed the survey. The overall degree of satisfaction was 5 (interquartile range [IQR] = 3-8). Among respondents without self-reported depression, stressors, or medical conditions (n = 3670), individuals taking DTE reported a higher median treatment satisfaction of 7 (IQR = 5-9) compared to other treatments. At the same time, the LT4 treatment group exhibited the lowest satisfaction of 5 (IQR = 3-7), and for the LT4 + LT3 treatment group, satisfaction was 6 (IQR = 3-8). Respondents taking DTE were also less likely to report problems with weight management, fatigue/energy levels, mood, and memory compared to those taking LT4 or LT4 + LT3. CONCLUSIONS: A subset of patients with hypothyroidism are not satisfied with their current therapy or their physicians. Higher satisfaction with both treatment and physicians is reported by those patients on DTE. While the study design does not provide a mechanistic explanation for this observation, future studies should investigate whether preference for DTE is related to triiodothyronine levels or other unidentified causes.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Peterson SJ, Cappola AR, Castro MR, et al. An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction. Thyroid. 2018. PMID: 29620972. doi:10.1089/thy.2017.0681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。